Agilent earns its premium valuation through superior execution, resilient revenue balance, and strong margin-driven growth.
Shares in Sanofi were sliding today after a double dose of bad news for its oral BTK inhibitor tolebrutinib, in development as a therapy for multiple sclerosis (MS). Along with what looks set to be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback